Biomedical Physiology and Immunotherapy Laboratories

Ashare Lab


Dr. Ashare's laboratory focuses on the role of lung macrophages in the development of regional inflammation in the lung in a number of lung diseases including: cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD) and asthma. Currently the laboratory is investigating the clinical manifestations and mechanisms of regional heterogeneity of lung inflammation, with an emphasis on increased understanding of differences in alveolar macrophage function in patient populations comparing alternate lobes of the lung. We are interested specifically in how regional differences in hypoxia impacts macrophage gene expression, phenotype and cell function and how these changes may contribute to this long-term problematic inflammatory response. This research overall aims to provide a sound molecular basis for improved diagnostics, therapies or treatments for CF, COPD and asthma.

Enelow Lab

Dr. Enelow's laboratory is primarily focused on the mechanisms responsible for severe lung pathology which occurs in the context of T cell recognition of antigen in the lung, both infectious and non-infectious.

Fiering Lab

Dr. Fiering's laboratory is primarily focused on in situ vaccination to generate therapeutic anti-tumor immunity

The immune system recognizes cancers and many are eliminated before they are clinically recognized. Cancer can be considered to be a failure of the immune system and it is now becoming clear that this immune failure is often due to active immunosuppression generated by the tumor.  One approach to cancer therapy is finding ways to stimulate the immune system to seek out and destroy tumor cells much like it seeks out and destroys infectious organisms.  Our lab is currently focused on developing novel approaches to boosting anti-tumor immunity by injection of immune stimulatory reagents directly into recognized tumors, an approach termed “in situ vaccination”.  The goal is to overcome the local immunosuppression, get an effective local antitumor immune response and generate a systemic antitumor immune response to fight metastatic disease. All vaccines include an antigen to be recognized by the immune system and an adjuvant to stimulate the response against the antigen.  For in situ vaccination the tumor carries all relevant antigens and injection of adjuvant into the tumor supports recognition of both tumor-associated and neoantigens expressed by the tumor. There are many options to how in situ vaccination can be performed and we explore the options in mice as well as working with dogs with spontaneous tumors and studying the local and systemic immune response involved.  The goal is to develop clinically useful in situ vaccination approaches.

Gilli Lab


Dr. Gilli's lab is interested in understanding the neuroimmunology of Multiple Sclerosis (MS) and its rodent models. Particularly, we are investigating the cellular and molecular pathways that contribute to neuroinflammation and central nervous system (CNS)-related tissue damage, aiming at understanding how inflammation contributes to neurodegeneration and disability progression in MS. The overall intention of this work is to identify new therapeutic targets or strategies that will improve our ability to manage progressive MS as well as other neurodegenerative diseases.

William Green lab

Dr. William Green's lab focuses on T cell immune responses to viral diseases; cell-mediated immunity to mouse retroviruses that cause either leukemia or immunodeficiency; immunity to the mouse acquired immunodeficiency syndrome (MAIDS) retroviral isolate and the mechanism of retroviral pathogenesis; studies on novel vaccine approaches.

Gulledge Lab

Dr. Gulledge's laboratory uses electrophysiological and imaging methods to record activity in individual neurons in cortical slices. Because there are many diverse classes of neurons in the cortex, and because these transmitters often have five or more receptor subtypes linked to different signaling pathways, a single transmitter can have many effects on cellular activity. For instance, acetylcholine can be both excitatory and/or inhibitory, depending upon the type of neuron and the duration of exposure to the transmitter. Revealing the interaction of these multiple signaling mechanisms is a core focus of the laboratory.

Hayden Lab

The Hayden Lab studies Cell Signaling in Inflammation, Autoimmunity, and Cancer; dysregulation of the immune response is a hallmark of a variety of disease states.  Unchecked innate and adaptive immunity can lead to chronic inflammation or autoimmunity, while compromised immune responses facilitate infection and tumorigenesis. The NF-kappaB signaling pathway is an essential mediator of communication amongst cells of the immune system and between the immune system and non-immune host cells.  Dysregulation of NF-kappaB in a variety of diseases, including autoimmunity, inflammation, and cancer, is well described.  In the Hayden lab, we are interested in elucidating the mechanisms leading to NF-kappaB dysregulation and are working to identify more selective approaches to manipulating the NF-kappaB pathway for in order to develop novel immunomodulatory therapies.

Howell Lab

The Howell lab studies the use of genome engineering using CRISPR/Cas to cleave both viral and cellular genes important for HIV infection and replication. We deliver these genes with lentiviral vectors and have shown we can both eliminate the HIV provirus from an infected cell as well as protect an uninfected cell from infection.

Lee Lab

Dr. Lee's laboratory uses high-throughput sequencing of B cell transcripts and high-resolution mass spectrometry to study the dynamics of antibody repertoires in infectious disease, autoimmune disease, and cancer. The repertoire of antibody molecules circulating in blood or coating mucosal surfaces is the basis for protective immunity, and we employ machine learning frameworks, big data analytics tools, proteomic analytical methods, and data modeling to gain clinically relevant insights regarding protective mechanisms at unprecedented details. Leveraging the knowledge, we aim to design next-generation therapeutics and vaccines precisely tailored to maximize effectiveness in the context of particular diseases and/or patients (i.e. personalized/precision medicine) through various protein engineering techniques and structural analysis.

Luikart Lab

Dr. Luikart's laboratory focuses on performing stable, precise, and well characterized genetic manipulations in mice and then evaluating the functional impact of the genetic manipulation using whole-cell electrophysiology and imaging.  It employs a variety of in vitro systems to gain molecular insight into the physiologically relevant phenotypes that are uncovered in vivo.

Pachner Lab

Our laboratory is focused on translational research in Multiple Sclerosis (MS), a chronic inflammatory, disabling disease of the CNS. We are working on both patients with MS and experimental models of MS in rodents to develop improved biomarkers and therapies. 

Pioli Lab

The Pioli lab is focused on identifying the molecular mechanisms that regulate macrophage activation in the context of both autoimmunity and cancer. Taking advantage of macrophage plasticity, we then use this information to determine how macrophage activation can be altered for maximal therapeutic benefit.

Rigby Lab

The Rigby lab focuses on autoimmunity of cystic fibrosis, innate and adaptive immunity in the immunopathogenesis of rheumatoid arthritis.

Robey Lab

The Robey lab studies regulation and function of mammalian hexokinases with specific emphasis on the interface between metabolism and cell survival in both adaptive (ischemic preconditioning) and maladaptive (cancer) contexts.

Stan Lab

The Stan laboratory studies the role of blood vessels in the pathogenesis of inflammatory disease and cancer. Using a broad variety of experimental approaches (e.g. genetically modified mouse models, cell biological approaches in cell culture and fluorescence and electron microscopy), our lab studies the biology of specific vascular endothelial gene products (i.e. PLVAP and interacting partners) and endothelial specific structures (e.g. fenestrae, caveolae, and vesiculo-vacuolar organelles) in normal cardiovascular function and the adaptive responses that occur in disease. A significant part of our work is devoted to developing novel therapeutic and diagnostic strategies for inflammation and cancer.

Tsongalis Lab

Dr. Tsongalis is the Director of the Laboratory for Clinical Genomics and Advanced Technologies (CGAT) at the Geisel School of Medicine. His area of expertise is in clinical molecular diagnostic applications. His research interests are in the pathogenesis of solid tumors, disease association of SNP genotyping and personalized medicine.